You are here

Press Releases from AlphaMed Press

Comment

Discuss

Embargo Policy: Articles for STEM CELLS and STEM CELLS Translational Medicine are embargoed for release until 9 a.m. Eastern U.S. time on the day the article is posted online. This policy applies to members of the media, authors, institutions' public information officers, and the public. Authors may not discuss their work with the media until 1 week before the mailing date or 1 week before online posting of the article, whichever is earlier, and must ensure that the media representatives agree to abide by the embargo policy. STEM CELLS Translational Medicine may refuse to publish a manuscript, despite acceptance for publication, if it has been prematurely released to the press.

April 3, 2017

DURHAM, NC - AlphaMed Press and the Cord Blood Association (CBA) are pleased to announce that STEM CELLS Translational Medicine (SCTM) is now the association’s official journal. With this partnership, SCTM will launch a new journal section dedicated to cord blood research.

“We are delighted to initiate this partnership with the Cord Blood Association,” said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and Director of the Wake Forest Institute for Regenerative Medicine. “With this new journal section, SCTM further expands the scope of new research reports for our readers – with the potential to accelerate progress in regenerative medicine.”

March 28, 2017

DURHAM, NC - Currently symptomatic therapies for Parkinson’s Disease (PD) produce unwanted side effects and diminished effectiveness over time. A recent study published in STEM CELLS suggests that human neural stem cell (hNSC) transplantation could help to treat PD by stimulating subventricular zone (SVZ) stem cells to produce more neural cells.

Strategies involving transplantation of these cells into the affected brain regions hold great promise; however, the exact mechanisms behind hNSCs’ success are not fully understood.

March 2, 2017

DURHAM, NC – A new study published this month in STEM CELLS Translational Medicine indicates that treating heart patients with mesenchymal stem cells (MSCs) does not increase their risk of irregular heart beat (arrhythmia). In fact, the MSCs had the opposite effect and showed promise of improving the condition.

“This could be an important breakthrough for many heart patients, as proarrhythmia – which is a new or more frequent occurrence of pre-existing arrhythmia – unfortunately can be a side effect of some of the drugs we’re using to treat these patients,” said the study’s lead author, Raul Mitrani, M.D., of the University of Miami School of Medicine’s Division of Cardiology (Miami, Florida).

August 18, 2016

DURHAM, NC - An infusion of a healthy donor’s unmodified stem cells might one day be used to prevent a type of osteoporosis caused by glucocorticoid therapy, according to a study published this month in STEM CELLS Translational Medicine. Osteoporosis is among the most significant side effects of glucocorticoid therapy, which is used for the management of inflammatory and auto-immune diseases.

August 15, 2016

DURHAM, NC - Researchers for the first time have shown how engineered stem cells can be used to deliver antibodies superior to those currently available for protecting against infectious diseases and biological warfare. The study appears in the August issue of STEM CELLS Translational Medicine.

August 5, 2016

DURHAM, NC - The medical world may be one step closer to an affordable, effective therapeutic vaccine for hepatitis C virus (HCV), according to a new study appearing in the latest issue of STEM CELLS Translational Medicine. The study, by scientists at Second Military Medical University in Shanghai, showed how exosomes secreted from umbilical mesenchymal stem cells (uMSC) efficiently suppressed HCV infection.

July 19, 2016

DURHAM, NC - A new study published in STEM CELLS Translational Medicine (SCTM) by Badner et al shows how a minimally invasive stem cell treatment in rats can reduce secondary damage in traumatic spinal cord injury (SCI). While similar studies have also demonstrated the promise of stem cells as a therapy for SCI, what makes this one different is the type of stem cell used. For the first time, researchers evaluated whether a brain-derived stromal cell would be better suited to target the acute phase of SCI than cells derived from other tissue sources. The answer was yes.

June 23, 2016

DURHAM, NC - In a new case report published today in STEM CELLS Translational Medicine, doctors at Odense University Hospital in Denmark detail how a patient who developed lymphedema after being treated for breast cancer benefitted from an injection of stem cells derived from adipose (fat) tissue. The results could change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment.

June 13, 2016

DURHAM, NC - A new study appearing in STEM CELLS Translational Medicine (SCTM) indicates that a single low dose of a patient’s own stem cells might offer relief from osteoarthritis of the knee.

Osteoarthritis (OA) is the most common chronic condition of the joints, resulting from the cartilage or cushion between the joints breaking down. This leads to pain, stiffness and swelling. OA is on the rise in the western world, in part because of the aging population and also because of obesity, which strains the joints by increasing the load they carry. Any joint in the body may be affected by OA, but it is particularly common in the knee.

May 9, 2016

DURHAM, NC - Treatment for full-term babies born with hypoxic-ischemic– brain damage due to blood and oxygen deprivation injuries is currently limited to therapeutic cooling to improve outcomes. There is no treatment for pre-term babies; however, a new study appearing in the latest issue of STEM CELLS Translational Medicine may lead to therapies that repair damage from hypoxia-ischemia.

Pages